NMNAT2 and glaucoma: Similarly, we have demonstrated that NMNAT2 immuno-labelling is decreased in late-stage glaucoma in the human retina and optic nerve head (ONH; a critical site of injury to RGC axons), where substantial RGC death has occurred6.